These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Association of characteristics of tampon use with menstrual toxic shock syndrome in France. Billon A; Gustin MP; Tristan A; Bénet T; Berthiller J; Gustave CA; Vanhems P; Lina G EClinicalMedicine; 2020 Apr; 21():100308. PubMed ID: 32382713 [TBL] [Abstract][Full Text] [Related]
24. Case report of an unusual presentation of Staphylococcus aureus induced toxic shock syndrome/hyperimmunoglobulinemia E syndrome. Jacob HS; Vercellotti GM; Leung DYM; Schlievert PM Medicine (Baltimore); 2020 Apr; 99(15):e19746. PubMed ID: 32282735 [TBL] [Abstract][Full Text] [Related]
25. Effect of non-absorbent intravaginal menstrual/contraceptive products on Staphylococcus aureus and production of the superantigen TSST-1. Schlievert PM Eur J Clin Microbiol Infect Dis; 2020 Jan; 39(1):31-38. PubMed ID: 31853743 [TBL] [Abstract][Full Text] [Related]
26. Development of a vaccine against Staphylococcus aureus invasive infections: Evidence based on human immunity, genetics and bacterial evasion mechanisms. Miller LS; Fowler VG; Shukla SK; Rose WE; Proctor RA FEMS Microbiol Rev; 2020 Jan; 44(1):123-153. PubMed ID: 31841134 [TBL] [Abstract][Full Text] [Related]
29. Contribution of toxic shock syndrome toxin-1 to systemic inflammation investigated by a mouse model of cervicovaginal infection with Staphylococcus aureus. Asano K; Narita K; Hirose S; Nakane A Med Microbiol Immunol; 2018 Nov; 207(5-6):297-306. PubMed ID: 29980843 [TBL] [Abstract][Full Text] [Related]
30. The Role of Antibiotics in Modulating Virulence in Staphylococcus aureus. Hodille E; Rose W; Diep BA; Goutelle S; Lina G; Dumitrescu O Clin Microbiol Rev; 2017 Oct; 30(4):887-917. PubMed ID: 28724662 [No Abstract] [Full Text] [Related]
31. Safety and Immunogenicity of a Parenterally Administered, Structure-Based Rationally Modified Recombinant Staphylococcal Enterotoxin B Protein Vaccine, STEBVax. Chen WH; Pasetti MF; Adhikari RP; Baughman H; Douglas R; El-Khorazaty J; Greenberg N; Holtsberg FW; Liao GC; Reymann MK; Wang X; Warfield KL; Aman MJ Clin Vaccine Immunol; 2016 Dec; 23(12):918-925. PubMed ID: 27707765 [TBL] [Abstract][Full Text] [Related]
32. The SaeRS Two-Component System Is a Direct and Dominant Transcriptional Activator of Toxic Shock Syndrome Toxin 1 in Staphylococcus aureus. Baroja ML; Herfst CA; Kasper KJ; Xu SX; Gillett DA; Li J; Reid G; McCormick JK J Bacteriol; 2016 Oct; 198(19):2732-42. PubMed ID: 27457715 [TBL] [Abstract][Full Text] [Related]
33. Intrauterine device infection causing concomitant streptococcal toxic shock syndrome and pelvic abscess with Actinomyces odontolyticus bacteraemia. Wu CM; Noska A BMJ Case Rep; 2016 Mar; 2016():. PubMed ID: 26965406 [TBL] [Abstract][Full Text] [Related]
34. Immunomodulation and Disease Tolerance to Staphylococcus aureus. Li Z; Peres AG; Damian AC; Madrenas J Pathogens; 2015 Nov; 4(4):793-815. PubMed ID: 26580658 [TBL] [Abstract][Full Text] [Related]
35. Staphylococcal toxic shock syndrome: superantigen-mediated enhancement of endotoxin shock and adaptive immune suppression. Kulhankova K; King J; Salgado-Pabón W Immunol Res; 2014 Aug; 59(1-3):182-7. PubMed ID: 24816557 [TBL] [Abstract][Full Text] [Related]
37. The contribution of group A streptococcal virulence determinants to the pathogenesis of sepsis. Reglinski M; Sriskandan S Virulence; 2014 Jan; 5(1):127-36. PubMed ID: 24157731 [TBL] [Abstract][Full Text] [Related]